Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
25-Feb-2026 | 5,508.5 | 5,655 | 5,468 | 5,625 | 22,777 | 1,28,35,49,761.5 | 1,40,076 |
26-Feb-2026 | 5,635 | 5,764.5 | 5,622.5 | 5,752 | 15,769 | 48,10,30,555.5 | 25,055 |
27-Feb-2026 | 5,752 | 5,781.5 | 5,614 | 5,639.5 | 21,098 | 74,44,49,948.5 | 94,409 |
02-Mar-2026 | 5,415 | 5,619.5 | 5,415 | 5,566 | 12,170 | 30,01,43,006 | 23,981 |
04-Mar-2026 | 5,489.5 | 5,536 | 5,432 | 5,466.5 | 17,876 | 47,99,12,496.5 | 56,532 |
05-Mar-2026 | 5,476.5 | 5,573.5 | 5,454 | 5,550 | 19,677 | 53,07,22,313 | 58,216 |
06-Mar-2026 | 5,580 | 5,583 | 5,497 | 5,530 | 7,433 | 22,84,17,248.5 | 21,934 |
09-Mar-2026 | 5,500 | 5,518.5 | 5,421 | 5,460 | 8,302 | 22,77,35,918 | 14,843 |
10-Mar-2026 | 5,509.5 | 5,664.5 | 5,500 | 5,616.5 | 20,289 | 71,55,51,111.5 | 59,014 |
11-Mar-2026 | 5,662 | 5,665 | 5,514.5 | 5,544.5 | 19,474 | 82,43,19,503.5 | 85,408 |
12-Mar-2026 | 5,515.5 | 5,528 | 5,400 | 5,444 | 17,850 | 66,49,47,280 | 67,357 |
13-Mar-2026 | 5,422 | 5,471.5 | 5,335.5 | 5,355.5 | 16,686 | 55,67,53,807 | 56,498 |
16-Mar-2026 | 5,393 | 5,407 | 5,233 | 5,323 | 21,767 | 1,08,42,58,559.5 | 1,31,678 |
17-Mar-2026 | 5,317 | 5,350 | 5,285 | 5,333.5 | 15,674 | 67,74,40,520.5 | 77,584 |
18-Mar-2026 | 5,335 | 5,423 | 5,315 | 5,351.5 | 18,597 | 35,12,17,645 | 35,775 |
19-Mar-2026 | 5,309 | 5,336 | 5,222.5 | 5,240 | 14,132 | 31,52,00,265.5 | 27,130 |
20-Mar-2026 | 5,245 | 5,298.5 | 5,211 | 5,257.5 | 20,696 | 1,71,17,85,107 | 2,17,535 |
23-Mar-2026 | 5,260 | 5,272.5 | 5,111.5 | 5,144.5 | 23,945 | 57,00,59,056.5 | 49,986 |
24-Mar-2026 | 5,200 | 5,304.5 | 5,160.5 | 5,297 | 14,266 | 41,50,56,209 | 37,565 |
25-Mar-2026 | 5,355 | 5,464 | 5,311.5 | 5,435.5 | 11,503 | 33,19,96,198 | 33,315 |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
